Therapeutic Effect Of Entecavir Combined With Cytokine Induced Killer Cells On HBeAg-positive Chronic Hepatitis B

ObjectiveTo explore the therapeutic effect and safety of entecavir(ETV) in combination with cytokine induced killer cells(CIK) on HBeAg-positive chronic hepatitis B. Indexes of therapeutic effect include normalization rate of ALT, undetectable rate of HBV DNA and negative conversion and seroconversion rate of serum HBeAg.MethodsFirstly, totally 50 patients with HBeAg-positive chronic hepatitis B were randomly divided into two groups. Twenty cases were treated with ETV combined with CIK as treatment group, while 30 cases were treated with ETV alone as control group.Secondly, peripheral blood of treatment group were collected and mononuclear cells were separated and cultured to CIK. The treatment group had CIK reinfusion and ETV, while the other group were treated with ETV alone. Hepatic function, HBV-M and HBV DNA were detected pre-treatment and at 12 weeks,24 weeks and 48 weeks post-treatment. Meanwhile, adverse reactions were evaluated.Lastly, by SPSS 17.0, statistical analyses of measurement data were conducted by Student’s t-test or x2 test.Results1. There were no difference of basal levels between the both groups pre-treatment(P>0.05).2. At 24 weeks post-treatment ALT and AST levels of both groups improved significantly and there were no difference of basal levels between the both groups(P>0.05). Normalization rate of ALT between both groups were 80%, 83.3%. Normalization rate of AST were 75%,73.3%.3. The undetectable rate of HBV DNA at 12 weeks,24 weeks and 48 weeks post-treatment were 45%、65%、80% in the treatment group and 40%、60%、 76.7% in the control group. There were all no difference of undetectable rate of HBV DNA between the both groups(P>0.05).4. The negative conversion and seroconversion rate of serum HBeAg at 48 weeks post-treatment were higher in the treatment group than that in the control group(60% vs 33.3% and 45% vs 16.7%,P<0.05). During the treatment, no obvious adverse reactions were seen except fever, headache or joint pain in fifteen patients when and after CIK cells were infused. There were no significant differences in kidney function and hemocytes.ConclusionETV in combination with CIK is safe and superior to ETV only in the treatment of HBeAg-positive chronic hepatitis B.1. Hepatic function of treatment group were significantly improve.2. Level of HBV DNA of treatment group were significantly decreased.3. The negative conversion and seroconversion rate of serum HBeAg at 48 weeks post-treatment were higher in the treatment group than that in the control group.4. During the treatment, no obvious adverse reactions were seen except fever.